On June 11, 2025, Nuvation Bio (parent company of AnHeart Therapeutics) announced that U.S. Food and Drug Administration (FDA) approved its drugTaletrectinib Adipate Capsules(herea...
June 4, 2025 – Hansoh Pharma announced that its innovative drugAlmonertinib Mesilate Tablets(UK brand name:Aumseqa®) has received marketing authorization from the UK Medicine...
On May 29th, the NMPA website announced the formal market approval of Genor Biopharma’s highly selective oral CDK4/6 inhibitor,Lerociclib Hydrochloride Tablets. It is indicated ...
On May 29, 2025, the latest announcement from the National Medical Products Administration (NMPA) revealed that ZELGEN Biopharmaceuticals' self-developed Gecacitinib Hydrochlor...
On May 21st, the NMPA website announced the approval of InnoCare’s CD19 targeting monoclonal antibodyTafasitamabfor marketing in China. It is indicated in combination with lenali...
On May 15, 2025, the latest announcement from the National Medical Products Administration (NMPA) revealed that Xuanzhu Biopharma’s self-developed Class 1 innovative anti-tumor ...
On March 10, 2025, the NMPA approved a new indication for Kelun-Biotech’s TROP2-targeting antibody-drug conjugate (ADC)Sacituzumab Tirumotecan for Injection. It is indicated for ...
On March 10, 2025, China's NMPA approved a new indication for Hansoh Pharma’sAlmonertinib Mesilate Tablets (Ameile®)for maintenance therapy inunresectable, locally advanced ...
On February 28, 2025, China's National Medical Products Administration (NMPA) officially announced the approval of the marketing application for Finotonlimab Injection (Anyou...
On February 7, 2024, the official website of China’s National Medical Products Administration (NMPA) announced the approval of the marketing application for Kelun-Biotech’s s...
January 2, 2025— The latest announcement on the official website of China’s National Medical Products Administration (NMPA) revealed that the second New Drug Application (NDA...
On December 23, 2024, China’s NMPA officially approved the new drug application ofStapokibart Injection, a Class 1 innovative biologic developed by KeyMed Biosciences, for the ...
Shanghai Office
Rm 208, Building 1, Universal Science & Technology Plaza, No. 958 Zhenbei Rd, Shanghai, China
Hanzhou Office
Rm 1802, Fl.18, Building 8, No. 19, Jugong Rd, Xixing Street, Binjiang District, Hangzhou, China
Jiaxing Office
No. 551, Yazhong Rd, Nanhu District, Jiaxing, China
FAB Japan
8F, 1 Chome-5-1 Kanda Ogawamachi, Chiyoda City, Tokyo 101-0052
Follow Us
Home
Services
Telephone
Message